Three decisions people often mix up
The UK marketing authorisation sets out approved treatment uses. NICE then assesses clinical and cost effectiveness for NHS use. NHS England and local integrated care boards organise how eligible patients enter commissioned services. This is why a private prescriber and a GP may give you different answers without disagreeing about the medicine.
NICE TA1026 recommends tirzepatide for adult weight management with a starting BMI of at least 35 and at least one weight-related comorbidity, alongside diet and activity measures. The recommendation adjusts BMI thresholds for specified ethnic backgrounds. Read it with the funding variation and the implementation information. It does not give you an unconditional right to a prescription on the day.
Why GP criteria can be narrower
The GP rollout puts people with the greatest clinical need first. Groups and start dates change over time, so an article repeating the original 2025 threshold is likely out of date. How ready local services are also shapes how assessment, prescribing and support are delivered.
The Cheshire and Merseyside NHS information, for example, describes a second access group from 23 June 2026. Check your current local pathway, because many areas have moved past their first group. Appointment arrangements and waiting times still differ between practices across England.
Specialist services and diabetes pathways
Specialist weight-management services work separately from the phased GP programme. A referral may involve assessing complex needs and discussing several treatments, including medicines and bariatric surgery. A referral does not guarantee Mounjaro will be the treatment chosen.
Prescribing for type 2 diabetes follows the diabetes pathway, and the obesity commissioning criteria alone do not decide it. If you already receive diabetes care, ask your diabetes team which recommendation applies to you. Never stop an existing medicine or describe a different diagnosis to get onto another pathway.
What to ask your GP or local service
Ask which service assesses eligibility in your area now, which commissioning group is open, whether you need a referral and how your diagnoses will be checked. If the service has not started yet, ask about current weight-management support and whether a review is planned.
Bring an accurate list of your medicines and details of any private prescription. NHS clinicians need to know about private treatment even when they are not prescribing it. Moving from private to NHS care is not automatic. A private clinic should never promise an NHS handover it cannot arrange.
Ongoing support is part of treatment
NHS England describes wraparound support covering nutrition, activity and your own clinical needs. Follow-up should look at side effects, how well treatment works, changes to other medicines and whether you can continue safely. A prescription on its own does not replace that support.
NICE advises a benefit-risk decision if you have lost less than 5% of your starting weight after six months at the highest dose you tolerate. This is a review point. Nobody should push you to the maximum dose regardless of side effects. England's arrangements are not the rules for Scotland, Wales or Northern Ireland.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- NICE TA1026: recommendations nice.org.uk
- NHS England: weight management injections england.nhs.uk
- NHS Cheshire and Merseyside: tirzepatide access cohorts cheshireandmerseyside.nhs.uk
- NICE: prescribing, reviewing and stopping tirzepatide nice.org.uk
Spotted something out of date? Report a mistake.